松康1号治疗去卵巢骨质疏松症大鼠的实验研究

Reserches on the therapeutic effect of Songkang No.1 on rats with ovariectomized osteoporosis

目的探讨松康1号对去卵巢骨质疏松症大鼠的治疗作用及机制。方法摘除雌性大鼠卵巢造绝经后骨质疏松症(PMOP)模型,造模成功后按照实验方案对大鼠进行灌胃治疗,6个月后采血、取样,行IL-6、TNF-α、PINP、β-CTX、骨密度等检测,骨组织蛋白提取测定ERK1/2、JNK蛋白表达情况。结果与模型组比较,松康1号高剂量组、中剂量组和低剂量组的ERK1/2、JNK蛋白、腰椎骨密度和股骨骨密度指标均值有显著统计学差异(P<0.05);与模型组比较,松康1号高剂量组、中剂量组和低剂量组的IL-6、TNF-α、β-CTX、和PINP指标均值有显著统计学差异(P<0.05)。其中以松康1号高剂量组效果最为明显。结论松康1号在一定程度上能够降低IL-6、TNF-α含量,改善骨转换及骨密度指标,并能够上调骨组织中ERK1/2和JNK蛋白的含量,使绝经后骨质疏松症得到改善。ERK1/2和JNK蛋白可能是今后治疗绝经后骨质疏松症的潜在靶点,但仍需进一步展开深入的研究。

Objective To explore the therapeutic effect and mechanism of Songkang No.1 on rats with ovariectomized osteoporosis. Methods Taking female rats with postmenopausal osteoporosis caused by ovariectomy as models, Songkang No.1 was used to treat rats by intragastric administration according to the established treatment plan. Results Compared with the model group, the mean values of ERK1/2, JNK and BMD indexes in the high dose group, the middle dose group, and the low dose group of Songkang No.1 had significant differences(P<0.05). Compared with the model group, the mean values of IL-6, TNF-α, β-CTX, and PINP indexes in the high dose group, the middle dose group, and the low dose group of Songkang No.1 had significant differences(P<0.05). Among all the control groups, Songkang No.1 high dose group had the most obvious effect. Conclusion Songkang No.1 can reduce the content of IL-6 and TNF-α, improve bone turnover index, and can up-regulate the content of ERK1/2 and JNK protein to a certain extent, which lead to curative effect on postmenopausal osteoporosis. ERK1/2 and JNK may be potential targets for future treatment of postmenopausal osteoporosis. but further research is needed.